Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.92, read 2026-11-08
Ethical passes the values gate
Price16.84 USD
Fair value13.51
Ethical score70.0/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Distribution16.51+2.0% to today Accumulation gives way to Distribution after an 11% slide in 5 weeks
2026-09-06Read Accumulation18.64-9.7% to today Markup gives way to Accumulation after a 28% rise in 4 weeks
2026-08-06Read Markup14.61+15.3% to today ✓Accumulation gives way to Markup after a 31% rise in 5 weeks
2026-07-02Read Accumulation11.15+51.0% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
NeoGenomics, Inc. holds its Accumulation at $16.84. The statistical read favours the buyers, held for 3 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 3 days
Price at the screen
$16.84
Valuation
N/A trailing · 52.42 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.83
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.11%
Below 33%
Interest-bearing debt is just 30.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
23.45%
Below 49%
Money owed to the company is 23.4% of assets, under the 49% limit.
Pass
Revenue purity
1.25%
Below 5%
Only 1.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
NeoGenomics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-08. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NEO's ethical verdict changes
Today NEO passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $13.51 fair value estimate, 11.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 24.6% above the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +31% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $13.51, with a range of $13.51 to $15.54, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cancer testing labs priced beyond their profits
When a biopsy heads off for analysis the work often lands in specialist labs like this one. Demand looks steady yet the business still posts losses, with revenue up just 11% and margins at minus 13%. Shares trade at 14.61 against a fair value of 10.87, a 26% stretch that leaves little margin for slips.
The forward multiple sits at 40 times while return on equity runs at minus 12%. Analysts carry a buy rating with a 16 median target, but the gap to our numbers shows the market is already paying for growth that has yet to turn into cash. No clear moat appears in the figures either.
Risks sit around execution and volume pressure in a competitive diagnostics space. One slower year could widen the losses without any buffer from current pricing. The ethical screen passes cleanly, yet the valuation does not.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NEO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Distribution$16.83+2.7%Entry 17
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 31% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15.
2026-10-28Distribution$16.39+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Distribution$16.39+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$16.39+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$16.39+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$16.39+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$16.39-5.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$17.25+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Distribution$17.25+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 33% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Distribution$17.25+4.5%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $15.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
